Effect of mesoglycan on macrorheologic and microrheologic parameters

Abstract Whole blood filtration, mean erythrocyte aggregation, and erythrocyte membrane fluidity were examined in 10 patients with vascular atherosclerotic disease (VAD) and in 15 VAD patients with noninsulin-dependent diabetes mellitus (NIDDM) treated with mesoglycan (100 mg orally twice a day) for 30 days. The red cell membrane transverse fluidity gradient was evaluated in the VAD subjects, and the red cell membrane protein lateral mobility was measured in the VAD subjects with NIDDM. In both groups, mesoglycan treatment was responsible for an increase in erythrocyte membrane fluidity. This finding, which reflects an improvement in the dynamic properties of red cell membrane, assumes part…

Erythrocyte membrane fluidity during mesoglycan treatment